Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 17;26(6):2703.
doi: 10.3390/ijms26062703.

Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches

Danielle Rasooly  1 , Alexandre C Pereira  1   2 , Jacob Joseph  1   3   4
Affiliations
Review

Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches

Danielle Rasooly et al. Int J Mol Sci. .

Abstract

Heart failure (HF) is a complex, heterogeneous syndrome with rising prevalence and high morbidity and mortality. The pathophysiology and diverse etiologies of HF present significant challenges for developing effective therapies. Omics technologies-including genomics, proteomics, transcriptomics, metabolomics, and epigenomics-have reshaped our understanding of HF at the molecular level, uncovering new biomarkers and potential therapeutic targets. Omics also enable insights into individualized treatment responses, the risks of adverse drug effects, and patient stratification for clinical trials. This review explores how multi-omics can enhance heart failure drug discovery and development across all stages of the therapeutic pipeline: (1) target selection and lead identification, (2) preclinical studies, and (3) clinical trials. By integrating omics approaches throughout the drug development process, we can accelerate the discovery of more effective and personalized therapies for heart failure.

Keywords: clinical trials; drug discovery; epigenomics; genomics; heart failure; metabolomics; multi-omics; omics; proteomics; transcriptomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
An overview of the various applications of multi-omics in drug discovery and development throughout the therapeutic pipeline.
See this image and copyright information in PMC

References

    1. Savarese G., Becher P.M., Lund L.H., Seferovic P., Rosano G.M.C., Coats A.J.S. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc. Res. 2022;118:3272–3287. doi: 10.1093/cvr/cvac013. - DOI - PubMed
    1. Sayed A., Abramov D., Fonarow G.C., Mamas M.A., Kobo O., Butler J., Fudim M. Reversals in the Decline of Heart Failure Mortality in the US, 1999 to 2021. JAMA Cardiol. 2024;9:585–589. doi: 10.1001/jamacardio.2024.0615. - DOI - PMC - PubMed
    1. Heidenreich P.A., Bozkurt B., Aguilar D., Allen L.A., Byun J.J., Colvin M.M., Deswal A., Drazner M.H., Dunlay S.M., Evers L.R., et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–e1032. doi: 10.1161/CIR.0000000000001063. - DOI - PubMed
    1. Carnicelli A.P., Clare R., Hofmann P., Chiswell K., DeVore A.D., Vemulapalli S., Felker G.M., Sarocco P., Mentz R.J. Characteristics and Outcomes of Patients with Heart Failure with Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. J. Am. Heart Assoc. 2021;10:e021276. doi: 10.1161/JAHA.120.021276. - DOI - PMC - PubMed
    1. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., Chioncel O., et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2023;44:3627–3639. doi: 10.1093/eurheartj/ehad195. - DOI - PubMed